Racial differences in lipid-lowering agent use in medicaid patients with cardiovascular disease

Medical Care

Volumn 42, Issue 10, 2004, Pages 1009-1018

  Litaker, David ^a   Koroukian, Siran M ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adherence; Cardiovascular disease; Medicaid; Racial disparities; Secondary prevention

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; CERIVASTATIN; CLOFIBRATE; COLESTIPOL; COLESTYRAMINE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; PROBUCOL; SIMVASTATIN;

ADULT; CARDIOVASCULAR DISEASE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DEMOGRAPHY; DRUG USE; ETHNIC GROUP; FEMALE; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAID; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PHARMACY; PRESCRIPTION; PREVENTIVE MEDICINE; RACE DIFFERENCE; RECIPIENT; RETROSPECTIVE STUDY; REVIEW; ARTICLE; COMPARATIVE STUDY; ECONOMICS; MEDICAL FEE; MIDDLE AGED; MINORITY GROUP; MULTIVARIATE ANALYSIS; NEGRO; RISK; STATISTICAL MODEL; TREATMENT OUTCOME; UNITED STATES;

ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; ANTILIPEMIC AGENTS; CARDIOVASCULAR DISEASES; CONFIDENCE INTERVALS; FEE-FOR-SERVICE PLANS; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MEDICAID; MIDDLE AGED; MINORITY GROUPS; MULTIVARIATE ANALYSIS; ODDS RATIO; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; UNITED STATES;

EID: 6344263681     PISSN: 00257079     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005650-200410000-00010     Document Type: Review

References (84)

1. Collaborative overview of randomized controlled trials of anti-platelet therapy in various categories of patients. BMJ. 1994;308:81-106.
2. Becker RC. Antiplatelet therapy in coronary heart disease. Arch Pathol Lab Med. 1993;117:89-92.
3. The Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease; the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
4. The Beta-blocker Heart Attack Study Group. The Beta-blocker Heart Attack Trial. JAMA. 1981;246:2073-2074.
5. Yusef S, Wittes J, Friedman L. Overview of results of randomized clinical trials in heart disease, I: treatments following myocardial infarction. JAMA. 1988;260:2088-2093.
6. Pederson TR. Six-year follow-up of the Norwegian multicenter study on timolol after acute myocardial infarction. N Engl J Med. 1985;313:1055-1058.
7. Holm I. An analysis of randomized trials evaluating the effect of cholesterol reduction on total mortality and coronary heart disease incidence. Circulation. 1990;82:1916-1924.
8. McCormick D, Gurwitz JH, Lessard D, et al. Use of aspirin, b-blockers, and lipid-lowering medications before recurrent acute myocardial infarction. Arch Intern Med. 1999;159:561-567.
9. Stenestrand U, Wallentin L. Early statin treatment following acute myocardial infarction and 1-year survival. JAMA. 2001;285:430-436.
10. Rochon PA, Tu JV, Anderson GM, et al. Rate of heart failure and 1-year survival for older people receiving low-dose beta-blocker therapy after myocardial infarction. Lancet. 2000;356:639-644.
11. Aronow HD, Topol EJ, Roe MT, et al. Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study. Lancet. 2001;357:1063-1068.
12. Cooper R, Cutler J, Desvigne-Nickens P, et al. Trends and disparities in coronary heart disease, stroke, and other cardiovascular diseases in the United States: findings of the National Conference on Cardiovascular Disease Prevention. Circulation. 2000;102:3137-3147.
13. Barnett E, Halverson J. Local increase in coronary heart disease mortality among blacks and whites in the United States, 1985-1995. Am J Public Health. 2001;91:1499-1506.
14. Barnett E, Halverson MA. Disparities in premature coronary heart disease mortality by region and urbanicity among black and white adults ages 35-64, 1985-1995. Public Health Rep. 2000;115:52-64.
15. Qureshi AI, Suri MF, Guterman LR, et al. Ineffective secondary prevention in survivors of cardiovascular events in the US population: report from the Third National Health and Nutrition Examination Survey. Arch Intern Med. 2001;161:1621-1628.
16. Schrott HG, Bittner V, Vittinghoff E, et al. Adherence to National Cholesterol Education Program treatment goals in postmenopausal women with heart disease: the Heart and Estrogen/Progestin Replacement Study (HERS). JAMA. 1997;277:1281-1286.
17. Jha AK, Varosy PD, Kanaya AM, et al. Differences in medical care and disease outcomes among black and white women with heart disease. Circulation. 2003;108:1089-1094.
18. Nelson K, Norris K, Mangione CM. Disparities in the diagnosis and pharmacologic treatment of high serum cholesterol by race and ethnicity: data from the Third National Health and Nutrition Examination Survey. Arch Intern Med. 2002;162:929-935.
19. vanRyn M. Research on the provider contribution to race/ethnicity disparities in medical care. Med. Care. 2002;40:I140-I151.
20. Laine C, Newschaffer CJ, Zhang D, et al. Adherence to retroviral therapy by pregnant women infected with human immunodeficiency virus: a pharmacy claims-based analysis. Obstet Gynecol. 2000;95:167-173.
21. Monane M, Bohn RL, Gurwitz JH, et al. Compliance with antihypertensive therapy among elderly Medicaid enrollees: the role of age, gender, and race. Am J Public Health. 1996;86:1805-1808.
22. Kotzan JA, Martin BC, Wade WE. Persistence with estrogen therapy in a postmenopausal Medicaid population. Pharmacotherapy. 1999;19:363-369.
23. Cooper WO, Hickson GB. Corticosteroid prescription filling for children covered by Medicaid following an emergency department visit or a hospitalization for asthma. Arch Pediatr Adolesc Med. 2001;155:1111-1115.
24. Barzagan M, Barbre AR, Hamm V. Failure to have prescriptions filled among black elderly. J Aging Health. 1993;5:264-282.
25. National Cholesterol Education Program (NCEP). Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Bethesda, MD: National Heart, Lung, and Blood Institute; September 1993.
26. Ray WA, Griffin MR. Use of Medicaid data for pharmacoepidemiology. Am J Epidemiol. 1989;129:837-849.
27. Robinson JR, Young TK, Roos LL, et al. Estimating the burden of disease: comparing administrative data and self-reports. Med Care. 1997;35:932-947.
28. Koroukian SM, Cooper GS, Rimm AA. Ability of Medicaid claims data to identify incident cases of breast cancer in the Ohio Medicaid population. Health Serv Res. 2003;38:947-960.
29. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45:613-629.
30. Ogle KS, Swanson GM, Woods N, et al. Cancer and comorbidity: redefining chronic diseases. Cancer. 2000;88:653-663.
31. Newschaffer CJ, Penberthy L, Desch CE, et al. The effect of age and comorbidity in the treatment of elderly women with nonmetastatic breast cancer. Arch Intern Med. 1996;156:85-90.
32. National Center for Health Statistics. Trends in serum cholesterol levels among US adults aged 20 to 74 years: data from the National Health and Nutrition Examination Surveys 1960 to 1980. JAMA. 1987;257:937-942.
33. Berman DM, Rodrigues LM, Nicklas BJ, et al. Racial disparities in metabolism, central obesity, and sex hormone-binding globulin in postmenopausal women. J Clin Endocrinol Metab. 2001;86:97-103.
34. Cook CB, Erdman DM, Ryan GJ, et al. The pattern of dyslipidemia among urban African-Americans with type 2 diabetes. Diabetes Care. 2000;23:319-324.
35. Nelson TL, Hunt KJ, Rosamond W, et al. Obesity and associated coronary heart disease risk factors in a population of low-income African-American and white women: the North Carolina WISE-WOMAN project. Prev Med. 2002;35:1-6.
36. Sempos CT, Cleeman JI, Carroll MD, et al. Prevalence of high blood cholesterol among US adults. An update based on guidelines from the second report of the National Cholesterol Education Program Adult Treatment Panel. JAMA. 1993;269:3009-3014.
37. Safford M, Eaton L, Hawley G, et al. Disparities in use of lipid-lowering medications among people with type 2 diabetes mellitus. Arch Intern Med. 2003;163:922-928.
38. Avorn J, Monette J, Lacour A, et al. Persistence of use of lipid-lowering medications: a cross-national study. JAMA. 1998;279:1458-1462.
39. Farmer KC. Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice. Clin Ther. 1999;21:1074-1090.
40. Frolkis J, Zyzanski S, Schwartz J, et al. Physician non-compliance with the 1993 National Cholesterol Education Program (NCEP-ATPII) Guidelines. Circulation. 1998;98:851-855.
41. Aronow WS. Underutilization of lipid-lowering drugs in older persons with prior myocardial infarction and a serum low-density lipoprotein cholesterol > 125 mg/dl. Am J Cardiol. 1998;82:668-669.
42. Fonarow GC, French WJ, Parsons LS, et al. Use of lipid-lowering medications at discharge in patients with acute myocardial infarction: data from the National Registry of Myocardial Infarction 3. Circulation. 2001;103:38-44.
43. Savoie I, Kazanjian A. Utilization of lipid-lowering drugs in men and women: a reflection of the research evidence? J Clin Epidemiol. 2002;55:95-101.
44. Watt P, Becker DM, Salaita K, et al. Hypercholesterolemia in patients undergoing coronary bypass surgery: are they aware, under treatment, under control? Heart Lung. 1988;17:205-208.
45. McBride PE, Schrott HG, Plane MB, et al. Primary care adherence to National Cholesterol Education Program guidelines for patients with coronary heart disease. Arch Intern Med. 1998;158:1238-1244.
46. Prochaska JO, DiClemente CC. The Transtheoretical Approach: Crossing Traditional Boundaries of Therapy. Homewood, IL: Dow Jones-Irwin; 1984.
47. Bandura A. Social Learning Theory. Englewood Cliffs, NJ: Prentice Hall; 1977.
48. Jaen CR, Stange KC, Nutting PA. Competing demands of primary care: A model for the delivery of clinic preventive services. J Fam Pract. 1994;38:166-171.
49. Nutting PA. Health promotion in primary medical care: problems and potential. Prev Med. 1986;15:537-548.
50. Whittle J, Conigliaro J, Good CB, et al. Do patient preferences contribute to racial differences in cardiovascular procedure use? J Gen Intern Med. 1997;12:267-273.
51. Mein S, Winkleby MA. Concerns and misconceptions about cardiovascular disease risk factors: a focus group evaluation with low-income Hispanic women. Hisp J Behav Sci. 1998;20:192-211.
52. Ayanian JZ, Landon BE, Landrum MB, et al. Use of cholesterol-lowering therapy and related beliefs among middle-aged adults after myocardial infarction. J Gen Intern Med. 2002;17:95-102.
53. Rathore SS, Lenert LA, Weinfurt KP, et al. The effects of patient sex and race on medical students' ratings of quality of life. Am J Med. 2000;108:561-566.
54. Einbinder LC, Schulman KA. The effect of race on the referral process for invasive cardiac procedures. Med Care Res Rev. 2000;57(suppl):162-180.
55. Schulman KA, Berlin JA, Harless W, et al. The effect of race and sex on physicians' recommendations for cardiac catheterization. N Engl J Med. 1999;340:618-626.
56. LaVeist TA, Nickerson KJ, Bowie JV. Attitudes about racism, medical mistrust, and satisfaction with care among African American and white cardiac patients. Med Care Res Rev. 2000;57(suppl):146-161.
57. Ferguson JA, Weinberger M, Westmoreland GR, et al. Racial disparity in cardiac decision making. Arch Intern Med. 1998;158:1450-1453.
58. Delacretaz D, Michalopoulos PG, Ruiz J, et al. Management of hyperlipidemia after coronary revascularization; follow up study. BMJ. 1998;316:1499.
59. Frolkis J, Blackburn GG, Pearce GL, et al. Usefulness of providing physicians the results of risk factor assessments and treatment recommendations at discharge after coronary artery bypass grafting. Am J Cardiol. 2000;86:455-457.
60. Giles WH, Anda RF, Jones DH, et al. Recent trends in the identification and treatment of high blood cholesterol by physicians. Progress and missed opportunities. JAMA. 1993;269:1133-1138.
61. Cohen MV, Byrne MJ, Levine B, et al. Low rate of treatment of hypercholesterolemia by cardiologists in patients with suspected and proven coronary artery disease. Circulation. 1991;83:1294-1304.
62. McCormick D, Gurwitz JH, Savageau J, et al. Differences in discharge medication after acute myocardial infarction in patients with HMO and fee-for-service medical insurance. J Gen Intern Med. 1999;14:73-81.
63. Marcelino JJ, Feingold KR. Inadequate treatment with HMG-CoA reductase inhibitors by health care providers. Am J Med. 1996;100:605-610.
64. Pearson TA, Peters TD. The treatment gap in coronary artery disease and heart failure: community standards and the post-discharge patient. Am J Cardiol. 1997;80:45H-52H.
65. Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol. 1997;50:105-116.
66. McDonald HP, Garg AX, Haynes RB. Interventions to enhance patient adherence to medication prescriptions. JAMA. 2002;288:2868-2879.
67. Matsui D, Joubert GI, Dykxhoorn S, et al. Compliance with prescription filling in the pediatric emergency department. Arch Pediatr Adolesc Med. 2000;154:195-198.
68. Ievers CE, Brown RT, Drotar D, et al. Knowledge of physician prescriptions and adherence to treatment among children with cystic fibrosis and their mothers. J Dev Behav Pediatr. 1999;20:335-343.
69. Ziegelstein RC. Adherence to medication regimens and recommended lifestyle changes in patients with cardiovascular disease. Adv Studies Med. 2003;3:150-156.
70. Benner JS, Glynn RJ, Mogun H, et al. Long-term persistence in use of statin therapy in elderly patients. JAMA. 2002;288:455-461.
71. Anderson NB. Appealing to diverse audiences: Reaching the African-American community. JAMA. 1995;87(suppl):647-649.
72. Brown CM, Segal R. Ethnic differences in temporal orientation and its implications for hypertension management. J Health Soc Behav. 1996;37:350-361.
73. Nieto FJ, Alonso J, Chambless LE, et al. Population awareness and control of hypertension and hypercholesterolemia: the Atherosclerosis Risk in Communities Study. Arch Intern Med. 1995;155:677-684.
74. Pearson TA, Laurora I, Chu H, et al. The Lipid Treatment Assessment Project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med. 2000;160:459-467.
75. Cooper-Patrick L, Gallo JJ, Gonzales JJ, et al. Race, gender, and partnership in the patient-physician relationship. JAMA. 1999;282:583-589.
76. Cooper LA, Roter DL. Patient-provider communication: the effect of race and ethnicity on process and outcomes of health care. In: Smedley BD, Stith AY, Nelson AR, eds. Unequal Treatment: Confronting Racial and Ethnic Disparities in Health Care. Washington, DC: National Academy Press; 2003.
77. Houston-Miller N, Hill M, Kottke TE, et al. The multilevel compliance challenge: recommendations for a call to action. Circulation. 1997;95:1085-1090.
78. Blank MB, Mahmood M, Fox JC, et al. Alternative mental health services: the role of the black church in the south. Am J Public Health. 2002;92:1668-1672.
79. Duan N, Fox SA, Derose KP, et al. Maintaining mammography adherence through telephone counseling in a church-based trial. Am J Public Health. 2000;90:1468-1471.
80. Guise BJ. Behavioral medicine strategies for heart disease prevention: the example of smoking cessation. Prev Cardiol. 2000;3:10-15.
81. Ward GW. How misconceptions deter maintenance. Urban Health. 1977;6:28-29.
82. Carson JL, Ray WA, Strom BL. Medicaid databases. In: Strom BL, ed. Pharmacoepidemiology. Philadelphia: John Wiley & Sons, Ltd; 2000:307-324.
83. Strom BL, Carson JL. Use of automated databases for pharmacoepidemiological research. Epidemiologic Reviews, 12th ed. Baltimore, MD: The Johns Hopkins University of Hygiene and Public Health; 1990:87-107.
84. Johnson RE, Vollmer WM. Comparing sources of drug data about the elderly. J Am Geriatr Soc. 1991;39:1079-1084.